Multi-channel electrochemical micro-fluidic chip detection platform as well as use method and application thereof
Through the multi-channel electrochemical microfluidic chip detection platform combined with the composite detection probe, the problems of long detection time, high cost, insufficient sensitivity and specificity in the prior art are solved, and fast, high throughput, low cost, and high sensitivity specific detection of reproductive tract pathogens is achieved.
Patent Information
- Application Number
- CN202510291436.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-12
- Publication Date
- 2025-06-10
AI Technical Summary
The prior art has problems of long detection time, high cost, insufficient sensitivity and specificity when detecting reproductive tract pathogens, especially in the case of early detection and mixed infections.
A multi-channel electrochemical microfluidic chip detection platform is used, combined with a composite detection probe, including Cas12a-crRNA complex and mesoporous silica nanoparticles encapsulated with methylene blue, and is detected by differential pulse voltammetry to achieve rapid, high-throughput, low-cost, and high-sensitive specific detection of reproductive tract pathogens.
It realizes rapid, high-throughput, low-cost, and high-sensitive specific detection of reproductive tract pathogens, with a detection limit as low as 0.8 fM, and can detect multiple targets simultaneously, suitable for early detection and mixed infection situations.
Smart Images

Figure CN120121681A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological detection technologies, and particularly relates to a multi-channel electrochemical microfluidic chip detection platform for rapid detection of reproductive tract pathogens, as well as a usage method and an application thereof. Background Art
[0002] Disclosing the information of this background art section is only intended to enhance the overall understanding of the present invention, and it is not necessarily regarded as an admission or an implication in any form that this information constitutes the prior art already known to those of ordinary skill in the art.
[0003] Reproductive tract pathogens are the main causes of reproductive tract infectious diseases. In the reproductive tract, common pathogens mainly include Mycoplasma hominis, Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), Ureaplasma urealyticum, Mycoplasma genitalium, human cytomegalovirus, herpes simplex virus type II, etc. Epidemiological investigations show that the pathogen detection rates vary in different regions, and the pathogens that are likely to infect patients of different age groups are also different. Mixed infections are becoming more and more common.
[0004] Currently, common diagnostic methods include traditional bacterial culture, immunological tests, and molecular biology techniques. Although the bacterial culture method has high specificity, it takes a long time and requires specialized laboratory conditions. Compared with the culture method, the immunological detection based on antigen-antibody interaction has a shorter detection time and higher efficiency, but it is limited by the host immune response and may not be detectable in the early stage of infection. Molecular techniques, such as qPCR and RT-qPCR, have high sensitivity and strong specificity, but they require complex equipment and are easily interfered with, which limits their use in personal life.
[0005] In addition, many patients infected with reproductive tract pathogens are reluctant to seek medical treatment in a timely manner due to privacy concerns, which further highlights the necessity of timely and convenient diagnostic solutions. In this context, POCT provides a promising alternative that can perform rapid detection without relying on central laboratory facilities. POCT can provide test results beside the patient, ensuring a more private and convenient testing experience, while improving accessibility and encouraging early medical intervention.
[0006] Therefore, there is an urgent need for a POCT tool that combines high throughput, low cost, high sensitivity, and strong specificity for detecting reproductive tract pathogens. Summary of the Invention
[0007] In order to overcome the above problems, the present invention provides a multi-channel electrochemical microfluidic chip detection platform, as well as a usage method and an application thereof.
[0008] To achieve the above technical objectives, the present invention adopts the following technical solutions: In the first aspect of the present invention, a multi-channel electrochemical microfluidic chip detection platform is provided. The detection platform includes a multi-channel microfluidic chip and a composite detection probe; Among them, the multi-channel microfluidic chip is bonded from top to bottom by a channel layer, a reaction layer, and a bottom layer; A sampling hole is provided at the center of the channel layer, and a plurality of ventilation holes are evenly distributed in a circumferential array on the periphery of the channel layer. A flow channel is provided between the sampling hole and the ventilation holes; A plurality of detection pools are evenly distributed on the periphery of the reaction layer; the ventilation holes correspond to the detection pools one by one; one end of the flow channel is communicated with the sampling hole, and the other end is communicated with the detection pool; A plurality of electrodes are evenly distributed on the periphery of the bottom layer, and the electrodes correspond to the detection pools one by one; The composite detection probe includes: a target recognition probe and a signal amplification probe; The target recognition probe includes a Cas12a-crRNA complex; The signal amplification probe includes mesoporous silica (MSN) nanoparticles encapsulated with methylene blue (MB).
[0009] In the second aspect of the present invention, an application of the multi-channel electrochemical microfluidic chip detection platform described in the first aspect in detecting genital tract pathogens is provided.
[0010] In the third aspect of the present invention, a method for using the multi-channel electrochemical microfluidic chip detection platform described in the first aspect is provided, including the following steps: Respectively add the target recognition probe and the signal amplification probe into the detection pool, then add the sample to be tested into the sampling hole. After incubating for a specified time, differential pulse voltammetry (DPV) detection is performed; Utilize the relationship between the concentration of the target substance and the electrochemical signal to realize the detection of the concentration of the target substance in the sample to be tested.
[0011] The beneficial effects of the present invention are as follows: The present invention provides a multi-channel electrochemical microfluidic chip detection platform, which realizes rapid, high-throughput, low-cost, highly sensitive and specific detection of genital tract pathogens.
[0012] Specifically, when the target substance is present, the target recognition probe Cas12a-crRNA complex specifically recognizes the target and forms a Cas12a-crRNA-Target triple body, activating the trans-cleavage activity. The activated Cas12a system cleaves the single-stranded region of G1 / G2 in the signal amplification probe, thereby releasing the encapsulated methylene blue. Methylene blue further promotes the methyl bromide redox reaction, promoting signal transduction, and thus realizing highly sensitive and specific quantitative detection of pathogens.
[0013] On this basis, through a multi-channel microfluidic chip, different crRNA sequences can be placed in the reaction pool respectively to simultaneously achieve highly sensitive detection of multiple targets. In the embodiments of the present invention, multi-target ultrasensitive detection of CT, CA, TV, and NG was successfully achieved, and the detection limit was as low as 0.8 fM. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The specification drawings forming a part of the present invention are used to provide a further understanding of the present invention. The schematic embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation to the present invention.
[0015] Figure 1 FIG. 1 is a schematic structural diagram and a physical diagram of a multi-channel microfluidic chip; wherein, 1 - sample addition hole, 2 - flow channel, 3 - ventilation hole, 4 - detection pool, 5 - electrode, 6 - channel layer, 7 - reaction layer, and 8 - bottom layer; Figure 2 FIG. 2 is for detecting the specific recognition and cleavage performance of the target recognition probe for the target. (A) crRNA(CT) is selected, dsDNA is CT, * represents a mixture of CA, TV, and NG, and 9 - 10 are CA, TV, and NG respectively; (B) crRNA(CA) is selected, dsDNA is CA, * represents a mixture of CT, NG, and TV, and 9 - 10 are CT, NG, and TV respectively; (C) crRNA(TV) is used in FIG. 3, dsDNA is Candida albicans, * represents a mixture of CA, NG, and CT, and 9 - 10 are CA, NG, and CT respectively; (D) crRNA(NG) is selected, dsDNA is NG, * represents a mixture of CA, CT, and TV, and 9 - 10 are CA, CT, and TV respectively; wherein M is DNA marker (20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 300, 400, 500 bp); Figure 3 FIG. 4 is the DPV response of different concentrations of CT; Figure 4 FIG. 5 is for optimizing the detection conditions. Among them, A is the influence of different ratios of Cas12a to crRNA concentration on the response signal, B is the target recognition time, and C is the influence of the trans-cleavage time on the response signal; Figure 5 FIG. 6 is the normalized electrochemical response signal generated by 1 pM CT, CA, TV, NG and the corresponding Cas12a-crRNA pair for four mixed samples (each non-target concentration is 10 pM and the target concentration is 1 pM); Figure 6 FIG. 7 is the volume of the solution shunted into eight detection pools; Figure 7The normalized electrochemical response signals generated by the Cas12a-crRNA pair for 1 pM CT, CA, TV, NG and four mixed samples on the multi-channel microfluidic chip; Figure 8 The electrochemical signal-to-noise ratios generated by detecting four clinical samples respectively on the multi-channel microfluidic chip. Detailed implementation manners
[0016] It should be noted that the following detailed description is exemplary and is intended to provide further illustration of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.
[0017] It should be noted that the terms used herein are only for describing specific implementation manners and are not intended to limit the exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, they indicate the presence of features, steps, operations, devices, components and / or combinations thereof.
[0018] The first typical implementation manner of the present invention provides a multi-channel electrochemical microfluidic chip detection platform, and the detection platform includes a multi-channel microfluidic chip and a composite detection probe; Among them, the multi-channel microfluidic chip is bonded from top to bottom by a channel layer, a reaction layer and a bottom layer; A sample loading hole is arranged at the center of the channel layer, and a plurality of ventilation holes are evenly distributed in a circumferential array on the periphery of the channel layer. A flow channel is arranged between the sample loading hole and the ventilation holes; A plurality of detection pools are evenly distributed on the periphery of the reaction layer; the ventilation holes correspond to the detection pools one by one; one end of the flow channel is communicated with the sample loading hole, and the other end is communicated with the detection pool; A plurality of electrodes are evenly distributed on the periphery of the bottom layer, and the electrodes correspond to the detection pools one by one; The composite detection probe includes: a target recognition probe and a signal amplification probe; The target recognition probe includes a Cas12a-crRNA complex; The signal amplification probe includes mesoporous silica (MSN) nanoparticles encapsulated with methylene blue (MB).
[0019] In one or more implementation manners, the materials of the channel layer, the reaction layer and the bottom layer are all polydimethylsiloxane (PDMS).
[0020] In one or more implementation manners, the thickness of the channel layer is 4 - 6 mm, preferably 5 mm.
[0021] In one or more embodiments, the thickness of the reaction layer is 4 - 6 mm, preferably 5 mm.
[0022] In one or more embodiments, the thickness of the bottom layer is 2 - 4 mm, preferably 3 mm.
[0023] In one or more embodiments, the ventilation holes, sample addition holes, and detection cells are all through holes.
[0024] In one or more embodiments, the diameter of the sample addition hole is 0.25 - 0.4 mm, preferably 0.3 mm.
[0025] In one or more embodiments, to ensure the stability of detection, the diameter of the detection cell is greater than that of the ventilation hole; the flow channel is arranged at the bottom of the channel layer.
[0026] Preferably, the diameter of the ventilation hole is 1.5 - 3 mm, preferably 2 mm.
[0027] Preferably, the diameter of the reaction cell is 5 - 7 mm, preferably 6 mm.
[0028] Preferably, the width of the flow channel is 0.08 - 0.12 mm, preferably 0.1 mm; the length of the flow channel is 14 - 16 mm, preferably 15 mm.
[0029] In one or more embodiments, the electrode includes a working electrode, a reference electrode, and a counter electrode.
[0030] Preferably, both the working electrode and the counter electrode are screen - printed carbon electrodes, and the reference electrode is Ag / AgCl.
[0031] In one or more embodiments, the mesoporous silica nanoparticles encapsulated with methylene blue (MB) include a G1 - DNA strand fixed to the surface of mesoporous silica through an amide bond, mesoporous silica adsorbed with methylene blue, and a G2 - DNA strand, and partial bases of the G1 - DNA strand are complementary base - paired with partial bases of the G2 - DNA strand.
[0032] The encapsulation of methylene blue (MB) is achieved by the complementary base - pairing of partial bases of the G1 - DNA strand and partial bases of the G2 - DNA strand.
[0033] Preferably, the preparation method of the mesoporous silica nanoparticles encapsulated with methylene blue (MB) includes: After activating the carboxyl-modified mesoporous silica nanoparticles and mixing them with methylene blue for incubation, the pores were blocked with G1-DNA strands and G2-DNA strands. After washing and drying, mesoporous silica nanoparticles encapsulating methylene blue (MB), namely MB@MSN-G1 / G2, were obtained.
[0034] Among them, the nucleotide sequence of the G1-DNA strand is as shown in SEQ ID NO:1.
[0035] Among them, the nucleotide sequence of the G2-DNA strand is as shown in SEQ ID NO:2.
[0036] Among them, the quantity ratio of the G1-DNA strand to the G2-DNA strand is 2:1.
[0037] In one or more embodiments, in the Cas12a-crRNA complex, the molar ratio of Cas12a to crRNA is (1-3):(1-4), preferably 3:4.
[0038] The second typical embodiment of the present invention provides the application of the multi-channel electrochemical microfluidic chip detection platform described in the first aspect in detecting reproductive tract pathogens.
[0039] In one or more embodiments, the reproductive tract pathogens include Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Candida albicans (CA), and Trichomonas vaginalis (TV).
[0040] In one or more embodiments, when detecting Chlamydia trachomatis (CT), the nucleotide sequence of the crRNA is as shown in SEQID NO:3; When detecting Neisseria gonorrhoeae (NG), the nucleotide sequence of the crRNA is as shown in SEQ ID NO:4; When detecting Candida albicans (CA), the nucleotide sequence of the crRNA is as shown in SEQ ID NO:5; When detecting Trichomonas vaginalis (TV), the nucleotide sequence of the crRNA is as shown in SEQ ID NO:6.
[0041] The third aspect of the present invention provides a method for using the multi-channel electrochemical microfluidic chip detection platform described in the first aspect, including the following steps: Respectively add the target recognition probe and the signal amplification probe into the detection pool, then add the sample to be tested into the sample addition hole. After incubating for a specified time, differential pulse voltammetry (DPV) detection is carried out; Utilize the relationship between the concentration of the target substance and the electrochemical signal to achieve the detection of the concentration of the target substance in the sample to be tested.
[0042] In one or more embodiments, the incubation time is 45 min to 2 h, preferably 1 h.
[0043] In one or more embodiments, during the differential pulse voltammetry (DPV) detection, the potential scanning range is -0.5 to 0 V.
[0044] To enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0045] Table 1 shows the nucleic acid sequences used in the present invention.
[0046] Table 1 Nucleic Acid Sequences
[0047] Example 1 Figure 1 FIG. shows the structural schematic diagram and the physical diagram of the multi-channel microfluidic chip.
[0048] The multi-channel microfluidic chip is bonded from top to bottom by a channel layer 6, a reaction layer 7, and a bottom layer 8; A sample addition hole 1 is provided at the center of the channel layer, and a plurality of ventilation holes 3 arranged in a circumferential array are evenly distributed on the periphery of the channel layer 6. A flow channel 2 is provided between the sample addition hole 1 and the ventilation holes 3; A plurality of detection pools 4 are evenly distributed on the periphery of the reaction layer 7; the ventilation holes 3 correspond to the detection pools 4 one by one; one end of the flow channel 2 is communicated with the sample addition hole 1, and the other end is communicated with the detection pool 4; A plurality of electrodes 5 are evenly distributed on the periphery of the bottom layer 8, and the electrodes 5 correspond to the detection pools 4 one by one.
[0049] Among them, the materials of the channel layer 6, the reaction layer 7, and the bottom layer 8 are all polydimethylsiloxane (PDMS).
[0050] The channel layer 6 and the reaction layer 7 have the same thickness, both being 5 mm, and the bottom layer 8 has a thickness of 3 mm.
[0051] The ventilation holes 3, the sample addition hole 1, and the detection pools 4 are all through holes. Among them, the diameter of the sample addition hole 1 is 0.3 mm, the diameter of the ventilation holes 3 is 2 mm, and the diameter of the detection pools 4 is 6 mm.
[0052] To ensure the stability of detection, the diameter of the detection pool 4 is larger than that of the ventilation hole 3. The detection pool 4 is located directly below the ventilation hole 3 and corresponds to the ventilation hole 3 one by one. At the same time, the flow channel 2 is arranged at the bottom of the channel layer 6.
[0053] The width of the flow channel 2 is 0.1 mm; the length of the flow channel 2 is 15 mm.
[0054] The electrode 5 is a commercial spce electrode, including a working electrode, a reference electrode and a counter electrode. The working electrode and the counter electrode are both screen-printed carbon electrodes, and the reference electrode is Ag / AgCl.
[0055] The width of the working electrode is 3 mm, and the widths of the reference electrode and the counter electrode are both 1 mm.
[0056] Example 2 Preparation of the multi-channel microfluidic chip: Place the well-mixed PDMS glue in a vacuum degasser to remove air bubbles. Then place the mold on a casting tray, slowly pour in the degassed PDMS, and let it stand for 10 min before transferring it to an oven for thermal curing. After the PDMS is cured, peel it off from the mold, and use a cutter and a punch to prepare a channel layer, a reaction layer and a bottom layer with specific dimensions and structures.
[0057] After removing the dust on the surfaces of the channel layer, the reaction layer and the bottom layer, pre-align the channel layer and the reaction layer through a calibration platform. After plasma treatment, place them on the calibration platform again to complete precise alignment. Operate the Z-axis upward table tray to make the channel layer and the reaction layer contact and bond, and heat in an 85°C oven for 30 min. Then remove the tray to complete the bonding. Align the working area of the SPCE with the detection cell, and seal and fix it to the bottom layer with an adhesive, and finally complete the preparation and assembly of the microfluidic device.
[0058] Example 2 Preparation of the signal amplification probe: Disperse 2 mg of carboxyl-functionalized MSN in MES buffer (pH = 6) containing 200 mM EDC and 50 mM NHS, shake for 30 min and then centrifuge to remove the supernatant. Wash the precipitate three times with MES buffer and Tris-HCl buffer respectively. Then add 200 μL of 40 μM G1 solution to the precipitate, shake and react at room temperature for 1 h, and centrifuge to discard the supernatant. Add 200 μL of saturated MB solution and mix well, and shake in the dark at room temperature overnight. After removing the supernatant, mix 200 μL of 40 μM G2 solution with the precipitate particles, and shake in the dark at room temperature for 4 h. After centrifugal separation, wash the precipitate repeatedly with Tris-HCl buffer until the supernatant is colorless to obtain MB@MSN-G1 / G2, and store it at 4°C for later use. All the above centrifugation operation parameters are 5000 rpm / min for 2 min.
[0059] Example 3 Specific recognition and cleavage performance of the target recognition probe for the target: The specific recognition and cleavage performance of the Cas12a-crRNA complex for target DNA was verified by polyacrylamide gel electrophoresis (PAGE), and the electrophoresis results of different reaction systems of Cas12a-crRNA with G1 / G2, target DNA, and mixed DNA (with and without target) were analyzed. As Figure 2 shown in A (using CT as the target), the bands in lanes 1, 2, 9 to 11 are G1 / G2, CT, CA, NG, and TV respectively. The band in lane 8 is produced by the mixed solution of non-target CA, NG, and TV. Comparing with lanes 9 to 11, the presence of the three DNAs can be seen in the band. Lane 3 is the binary complex solution of Cas12a-crRNA, and no obvious band can be observed. Lane 4 is the ternary complex solution of Cas12a-crRNA(CT)-CT. No band was observed in lane 4. Comparing with lane 2, this confirmed that Cas12a-crRNA(CT) successfully recognized CT and cleaved it. The Cas12a-crRNA(CT)-CT ternary complex was incubated in the G1 / G2 solution for 45 min, and the reaction solution was added to lane 5 without the appearance of a band, indicating that the trans-cleavage performance of the ternary complex was activated. The band that appeared in lane 6 is the mixed solution of Cas12a-crRNA(CT) and G1 / G2. Comparing with the band of G-DNA in lane 1, it was confirmed that Cas12a-crRNA would not recognize and cleave G1 / G2 in the absence of the target. The band that appeared in lane 7 is the mixed solution of Cas12a-crRNA with four non-targets of G1 / G2, CA, NG, and TV. By comparing with lanes 5, 8 to 11, it was again shown that the specific recognition and cleavage function of Cas12a-crRNA, and at the same time, it was verified that in the presence of non-target DNA, the unactivated Cas12a-crRNA did not have trans-cleavage function and would not damage G1 / G2.
[0060] Expansion experiments were carried out with CA ( Figure 2 in B), NG ( Figure 2 in C), and TV ( Figure 2 in D) as targets for verification. The results showed that: only when the corresponding Cas12a-crRNA coexisted with the target DNA, the Cas12a-crRNA complex activated the trans-cleavage activity, and the presence of non-target DNA did not affect the specific recognition. The experimental results fully demonstrated that the Cas12a-crRNA system has strict specific recognition ability, and the activation of its trans-cleavage activity strictly depends on the accurate recognition of target DNA, showing good anti-interference performance in the detection of complex biological samples.
[0061] Example 4 Electrochemical analysis of the signal amplification probe: As Figure 3As shown, in the absence of the target DNA (targeting CT), only very weak redox peaks (black curve) were observed, indicating that the signal amplification probe MB@MSN-G1 / G2 bioconjugate maintained effective sealing. The low background might be due to the weak interaction between the MB molecule and the G1 / G2 gating molecules. In contrast, the presence of 1 fM CT led to an obvious MB characteristic peak around -0.296 V (red curve). This confirmed that the trans-cleavage activity of the Cas12a system was activated, releasing the MB molecules encapsulated within the MSN by cleaving G1 / G2. Additionally, as the CT concentration increased to 1 pM (blue curve) and 1 nM (green curve), the observed peak current gradually increased, confirming the detection ability of this detection strategy for CT.
[0062] Example 5 Optimization of detection conditions: To achieve the best performance of the sensing strategy, the mixing concentration ratio of Cas12a and crRNA, the target recognition time, and the trans-cleavage time were optimized using 1 nM CT. As the core of target recognition and controllable MB release, the mixing ratio of Cas12a and crRNA has an important impact on the detection sensitivity. Cas12a with a final concentration of 100 nM, 75 nM, 50 nM was mixed with different concentrations of crRNA (100 nM, 75 nM, 50 nM) for CT recognition and detection. According to A in Figure 4 the following study selected the mixing ratio of Cas12a and crRNA as 3:4.
[0063] The target recognition time optimization experiment showed ( Figure 4 in B), the DPV signal rapidly increased within 30 min and reached a plateau, indicating that the CT recognition process was completed. 30 min was selected as the target recognition time. Subsequently, the trans-cleavage time was optimized, that is, the incubation time of the Cas12a-crRNA-CT triple and the MB@MSN-G1 / G2 bioconjugate. As shown in C in Figure 4 the obtained response signal continuously increased with the increase of the trans-cleavage time and reached a plateau at around 45 min. Thereafter, the extension of the cleavage time did not cause an obvious change in the signal because the Cas12a-crRNA-target triple became inactivated after multiple rounds of cleavage. Therefore, 45 min was sufficient for the Cas12a-crRNA-target triple to cleave the encapsulation of the MB@MSN-G1 / G2 biocomplex.
[0064] Example 6 To evaluate the applicability of the sensing strategy and the specificity of detecting target DNA in complex hybrid DNA, an interference experiment was designed. Four kinds of DNA (double strands after annealing of TS and NTS) were mixed and added to the Cas12a-crRNA duplex (the final concentration of the target DNA was 1 pM, and the concentrations of the three non-target DNAs were 10 pM). The reaction was carried out for 30 min, and then it was added to the washed MB@MSN-DNA for reaction for 45 min. The two detection results of the mixed sample were compared with the detection result of a single sample (1 pM) ( Figure 5 ), and we found that Cas12a-crRNA accurately recognized the complex mixture containing the corresponding crRNA recognition sequence respectively, and there was a good correlation between the signal intensities based on single samples. These results demonstrated that Cas12a-crRNA could specifically detect DNA sequences with high sensitivity in the face of complex samples.
[0065] Example 7 Verify the flow effect of the multi-channel microfluidic chip: For the sample addition operation, a flat-headed syringe with a diameter of 0.45 mm was used to inject the test solution into the chip through the sample addition hole. It should be noted that the PDMS substrate is elastic, the diameter of the sample addition hole is smaller than the diameter of the syringe head, and a self-sealing structure can be formed when the syringe intervenes. At the same time, uniform liquid flow distribution is achieved through the Bernoulli effect. To verify that the fluid can be equally divided, after injecting 320 μL of MB solution, a Hamilton microsyringe was used to measure the solution volume in each detection pool. The results showed that the relative deviation of the solution volume in the 8 detection pools was 0.38% ( Figure 6 ), which confirmed that the designed chip had excellent shunt uniformity.
[0066] Example 8 An eight-channel detection pool structure design was adopted (as shown in Figure 1 ). Among them, the detection pools were divided into two groups according to their functions: the experimental group was pre-embedded with a Cas12a-crRNA complex solution and an MB@MSN-G1 / G2 probe system, and the adjacent control group was loaded with a Cas12a solution without crRNA and the same probe as a blank reference. Every two detection pools formed a spatially adjacent positive and negative control unit.
[0067] By injecting a mixed solution of four kinds of DNA (double strands after annealing of TS and NTS) (each final concentration was 1 pM) into the detection pool pre-embedded with the Cas12a-crRNA solution and the MB@MSN-G1 / G2 signal amplification system through the sample addition hole, after reacting for 1 h, differential pulse voltammetry (DPV) was used for electrochemical detection. The results are as shown in Figure 7As shown. By comparing the DPV characteristic peak current intensities of the mixed sample and the single target DNA sample, the parallel detection ability of multiple components in the chip system was verified, and the technical feasibility of the integrated microfluidic chip for synchronous analysis of multiple targets in complex samples was confirmed.
[0068] Example 9 To evaluate the detection reliability of the multi-channel microfluidic chip in complex real samples, clinical samples (No. 1-4) from different patients were used for verification. The results are as Figure 8 , Sample No. 1 and Sample No. 2 were positive for CT and NG respectively, while all four pathogens in Samples No. 3 and No. 4 showed negative results, which were consistent with the clinical test results. This confirmed that this biosensing strategy can still maintain the specific recognition ability for target DNA under complex matrices, meeting the sensitivity and anti-interference requirements of clinical diagnosis.
[0069] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention can have various changes and modifications. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.
Claims
1. A multi-channel electrochemical microfluidic chip detection platform, characterized in that: The detection platform includes a multi-channel microfluidic chip and a composite detection probe; Among them, the multi-channel microfluidic chip is composed of a channel layer, a reaction layer and a bottom layer bonded from top to bottom; A sample loading hole is arranged at the center of the channel layer, a plurality of ventilation holes are evenly distributed in a circular array on the circumference of the channel layer, and a flow channel is arranged between the sample loading hole and the ventilation holes; A plurality of detection pools are evenly distributed around the reaction layer; the ventilation holes correspond to the detection pools one by one; one end of the flow channel is connected to the sample addition hole, and the other end is connected to the detection pool; A plurality of electrodes are evenly distributed around the bottom layer, and the electrodes correspond to the detection cells one by one; The composite detection probe includes: a target recognition probe and a signal amplification probe; The target recognition probe includes a Cas12a-crRNA complex; The signal amplification probe comprises mesoporous silica nanoparticles encapsulating methylene blue.
2. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: The channel layer, reaction layer and bottom layer are all made of polydimethylsiloxane; Or, the thickness of the channel layer is 4-6 mm, preferably 5 mm; Or, the thickness of the reaction layer is 4-6 mm, preferably 5 mm; Alternatively, the thickness of the bottom layer is 2 to 4 mm, preferably 3 mm.
3. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: The vent hole, sample addition hole and detection pool are all through holes; Alternatively, the diameter of the sample addition hole is 0.25-0.4 mm, preferably 0.3 mm.
4. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: The diameter of the detection pool is larger than the diameter of the vent hole; the flow channel is arranged at the bottom of the channel layer; Preferably, the diameter of the vent hole is 1.5-3 mm, preferably 2 mm; Preferably, the diameter of the reaction cell is 5 to 7 mm, preferably 6 mm; Preferably, the width of the flow channel is 0.08-0.12 mm, preferably 0.1 mm; the length of the flow channel is 14-16 mm, preferably 15 mm.
5. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: The electrodes include a working electrode, a reference electrode and a counter electrode; Preferably, the working electrode and the counter electrode are both screen-printed carbon electrodes, and the reference electrode is Ag / AgCl.
6. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: Mesoporous silica nanoparticles encapsulating methylene blue (MB) include a G1-DNA chain fixed to the surface of the mesoporous silica via an amide bond, mesoporous silica adsorbed with methylene blue, and a G2-DNA chain, wherein some bases of the G1-DNA chain are complementary paired with some bases of the G2-DNA chain; Preferably, the method for preparing the mesoporous silica nanoparticles encapsulating methylene blue (MB) comprises: After the carboxyl-modified mesoporous silica nanoparticles were activated, they were mixed and incubated with methylene blue, and the pores were sealed with G1-DNA chains and G2-DNA chains. After washing and drying, mesoporous silica nanoparticles MB@MSN-G1 / G2 encapsulated with methylene blue (MB) were obtained. Wherein, the nucleotide sequence of the G1-DNA chain is shown in SEQ ID NO: 1; Wherein, the nucleotide sequence of the G2-DNA chain is shown in SEQ ID NO: 2; Among them, the ratio of the number of G1-DNA chains to G2-DNA chains is 2:
1.
7. The multi-channel electrochemical microfluidic chip detection platform according to claim 1, characterized in that: In the Cas12a-crRNA complex, the molar ratio of Cas12a to crRNA is (1-3): (1-4), preferably 3:
4.
8. Use of the multi-channel electrochemical microfluidic chip detection platform according to any one of claims 1 to 7 in detecting reproductive tract pathogens.
9. The method for using the multi-channel electrochemical microfluidic chip detection platform according to any one of claims 1 to 7, characterized in that: The steps include: Add target recognition probes and signal amplification probes to the detection pool respectively, then add the sample to be tested to the sample well, incubate for a specified time, and then perform differential pulse voltammetry (DPV) detection; The relationship between the concentration of the target substance and the electrochemical signal is used to detect the concentration of the target substance in the sample to be tested.
10. The method of use according to claim 9, characterized in that: During the differential pulse voltammetry (DPV) detection process, the potential scanning range was -0.5~0 V.
Citation Information
Cited By
Multi-nucleic acid probe rapid modification and multi-target detection device based on electric field regulation and control
CN120847211A
Rapid modification of multi-nucleic acid probes and multi-target detection device based on electric field regulation
CN120847211B
